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cians’ cost estimates for commonly prescribed drugs. In fact,
physicians’ with inaccurate cost estimates were more likely to be
comfortable with both GSPs and RDPs. Physicians have explicit
opinions regarding the clinical and economic ramiﬁcations of
GSPs and RDPs, and these opinions should be considered in
planning and communicating drug policies.
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OBJECTIVE: To assess the cost and outcomes of a disease man-
agement program (DMP) for the bleeding disorder population
insured by a state insurance plan. METHODS: All bleeding dis-
order patients covered by the plan were enrolled into a DMP
administered by the Indiana Hemophilia & Thrombosis Center
(IHTC). A pre/post intervention study design was used, with a
prior year serving as the baseline period and 1-year post enroll-
ment as the study period. Claims data were used to assess hos-
pitalizations, ER visits, total medical costs and factor costs.
Medical records were used to assess disease severity and other
co-morbidities. T-tests and a regression analysis were used to
assess the impact of the DMP. RESULTS: Thirty continuously
enrolled patients had complete data. Due to the small sample size
and large variability in costs found in this population, none of
the analyses reached statistical signiﬁcance. Approximately 90%
of the population was male, 87% with hemophilia A. The
average cost of care in the baseline year and follow-up year were
$110,637 and $111,329 respectively (p = 0.99). Although factor
use increased by 29,625 units (p = 0.46), and accounted for
90.4% and 96.9% of costs, baseline versus ﬁrst year respectively,
the mean number of inpatient hospital days and ER visits
decreased from 1.36 and 1.6 to 0.43 (p = 0.12), and 0.43 (p =
0.23) respectively. The average total cost for patients who
switched to the DMP during the study period decreased from
$136,725 to $97,557 (p = 0.40) from baseline. CONCLUSION:
Although the DMP did not appear to statistically decrease total
costs, costs were contained even as factor utilization increased.
Additionally, there was a trend toward lower inpatient hospital
days and ER visits. Further enrollment may increase statistical
power and a longer study period will be used to completely assess
the impact of the DMP.
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OBJECTIVE: The Medicare Modernization Act of 2003 requires
drug plan sponsors to provide medication therapy management
(MTM) programs to beneﬁciaries with 1) annual drug expendi-
tures above $4000; 2) multiple comorbidities; and 3) multiple
prescription drugs. The purpose of this study was to obtain
nationally representative estimates of the proportion of seniors
who met the expenditure criteria and identify risk factors for
high annual drug expenditures. METHODS: Prescribed medi-
cines and demographic data came from the 2002 and 2003
Medical Expenditure Panel Survey (MEPS) for respondents ≥65
years of age. Survey-weighted logistic regression identiﬁed risk
factors for high drug expenditures. Candidate variables included
age, gender, race, income, education, marital status, functional
limitations, health status, presence of chronic conditions, body
mass index (BMI), and medical and prescription drug insurance.
Standard errors (SEs) were adjusted for complex survey design
and expenditures were adjusted to 2003 U.S. dollars. Annual
expenses of $3810 in 2003 were deemed equivalent to $4000 in
2005. RESULTS: An estimated 9.2% (SE ± 0.4%) of 36 million
seniors over 2002 and 2003 incurred more than $3810 annual
drug expenditures, accounting for 35% of $55.3 billion in drug
expenditures among all seniors. Respondents with high drug
expenditures reported 10.8 (±0.2) unique medications with
77.9% (±1.9%) reporting ≥8 medications; all had ≥3 medica-
tions. These respondents also had 5.2 (±0.1) chronic conditions;
60.5% (±2.3%) had ≥4 conditions. Diabetes, hyperlipidemia,
depression, and cardiac disease signiﬁcantly increased the risk of
high drug expenditures. Other signiﬁcant risk factors included
receiving help with activities of daily living (ADLs), housework
limitations, high BMI, fair/poor health, and total number of
chronic diseases. CONCLUSION: Respondents with drug
expenditures exceeding the MTM threshold obtain signiﬁcantly
more drugs and have a higher disease burden than those with
lower drug expenditures. Characteristics other than the number
and type of medications can be used to identify candidates for
MTM programs.
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OBJECTIVES: This study examined the prevalence and patterns
of inappropriate medication use among older Medicare managed
care beneﬁciaries enrolled in a Southern California Social Health
Maintenance Organization. METHODS: The administrative
datasets used for the analysis contained demographics, enroll-
ment information, pharmacy claims, inpatient and outpatient
utilization for approximately 75,000 older Medicare beneﬁcia-
ries. The analytical sample included 47,978 members with con-
tinuous enrollment from July 1st 2004 to June 30th 2005. This
study was based on the inappropriate medication list developed
by Zhan (2001). The list was limited to medications that should
always be avoided or considered rarely appropriate regardless of
dose or diagnosis. Patients with at least one prescription claim
for an inappropriate medication were compared to patients
without. Different patterns of inappropriate medication use were
identiﬁed. Univariate and multivariate analyses were performed
to examine characteristics associated with these patterns.
RESULTS: 17.3% (8313/47,978) of the members ﬁlled at least
one claim for a potentially inappropriate medication. 51.2%
(4260/8313) of them ﬁlled multiple prescriptions for potentially
inappropriate medications. The average number of prescribing
providers was higher for members with inappropriate medica-
tions than for those without inappropriate medication claims
(3.84 vs. 2.69, p < 0.0001). Members with inappropriate med-
ication claims ﬁlled an average of 45 medications per year (vs.
32 for other members, p < 0.0001). Logistic regression showed
that inappropriate medication use was associated with younger
age (Odds ratio conﬁdence interval: 0.978–0.985), female gender
(CI:0.612–0.683), number of prescribing providers (CI:1.289–
1.320), and use of home and community-based services —HCBS-
(CI:1.281–1.434). Members who were younger (p = 0.0018),
female (p = 0.0030), dually eligible for Medicare and Medicaid
(p < 0.0001) and using HCBS (p < 0.0001) were more likely to
use multiple inappropriate medications. CONCLUSIONS:
The rate of inappropriate medication use was similar to rates
found in the literature but revealed the importance to develop
